Clinical trials: Multiple Sclerosis Relapsing Remitting
Multiple Sclerosis, Relapsing-Remitting
Efficacy of Diet on Quality of Life in Multiple Sclerosis
The overarching goal of this project is to critically evaluate the efficacy of incorporating dietary guidance within multiple sclerosis (MS) care for improving long-term quality of life (QoL) compared to usual care.
- Trial name
- EDQ (NCT05007483)
- Testing
- BodyBio Balance Oil, Kirunal Fish Oil, BodyBio PC
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Terry L. Wahls
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
The goal of this clinical trial is to evaluate the safety and tolerability of terfenadine when added to standard first-line disease-modifying therapy in adults with multiple sclerosis.
- Trial name
- NCT07827716
- Testing
- Terfenadine, Standard First-line Disease-Modifying Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chuan Qin
Multiple Sclerosis, Relapsing-Remitting
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve…
- Trial name
- MS-HDtDCS (NCT05958381)
- Testing
- Transcranial Direct Current Stimulation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The University of Texas at Dallas
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT06408259
- Testing
- Ozanimod, Fingolimod
- Where
- 33 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- Bristol-Myers Squibb
Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- SIZOMUS (NCT03783416)
- Where
- United Kingdom
- Volunteers
- 72 people
- Sponsor
- Queen Mary University of London
Relapsing Remitting Multiple Sclerosis
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
The MS pilot study will assess the safety and investigate the remyelinating effects of the SetPoint System (study device) in adult patients diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT06796504
- Testing
- Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation
- Where
- 9 sites in United States
- Volunteers
- 60 people
- Sponsor
- SetPoint Medical Corporation
Multiple Sclerosis, Relapsing-Remitting
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment…
- Trial name
- DELIVER-MS (NCT03535298)
- Testing
- Early Highly Effective Therapies Group, Escalation Therapies Group
- Where
- 30 sites in United States, United Kingdom
- Volunteers
- 800 people
- Sponsor
- The Cleveland Clinic
Multiple Sclerosis (MS) - Relapsing-remitting
Synbiotic Supplementation as a Part of Dietary Modification in Multiple Sclerosis
Multiple Sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system, influenced by genetic, epigenetic, and immunological factors, as well as environmental factors such as nutrition.
- Trial name
- Synbiotic-MS (NCT07789171)
- Testing
- MNT+Synbiotic
- Where
- Turkey (Türkiye)
- Volunteers
- 38 people
- Sponsor
- Hacettepe University
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
The study is an investigator-run, study following participants for 2 years with twice-daily remibrutinib. MRI is the main endpoint. Safety, tolerability, and efficacy are secondary endpoints.
- Conditions
- Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
- Trial name
- RemiSeven (NCT07222956)
- Testing
- Remibrutinib (Open Label)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Moein Amin
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
- Trial name
- DanNORMS (NCT04688788)
- Testing
- Rituximab, Ocrelizumab, Fexofenadine
- Where
- 11 sites in Denmark
- Volunteers
- 600 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Sclerosis
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS).
- Trial name
- OCARINA 3 (NCT07667322)
- Testing
- Ocrelizumab Co-formulated With rHuPH20
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Ocrevus on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04448977
- Testing
- Ocrevus
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis, Relapsing-Remitting
Examining Effects of Tysabri on Cognitive Fatigue Using fMRI
The purpose of this research study is to investigate the effectiveness of Tysabri on cognitive fatigue in persons with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT04565431
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis (MS) Relapsing Remitting
Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)
The investigators propose a multi-center pilot study, which aims to evaluate safety and efficacy of fumarates as de-escalation therapy in clinically stable MS patients previously treated with anti-CD20 therapy.
- Trial name
- NCT07757568
- Testing
- Vumerity, Tecfidera
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Colorado, Denver
Multiple Sclerosis (MS) - Relapsing-remitting
Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
REDEFINE-MS is a research study for people with relapsing multiple sclerosis (MS) who are participating in the RESHAPE-MS trial.
- Trial name
- REDIFINE MS (NCT07758270)
- Testing
- Remibrutinib, Ocrelizumab (US)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis
WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis
This study is a randomized controlled trial (RCT) that compares the effects of two different 12-month aerobic walking exercise programs on cognitive processing speed (CPS), brain MRI, and other functional outcomes in 32 adults…
- Trial name
- NCT05755061
- Testing
- GEMS Plus, GEMS
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Kessler Foundation
Multiple Sclerosis, Relapsing-Remitting
Cognitive Disability and Quality of Life of Patients Suffering From Multiple Sclerosis and Treatment With Immunosuppressant
Multiple Sclerosis is the first cause of neurological handicap in France. The importance of cognitive disabilities, their evaluation and their impact on patients' life have only been comprehended recently.
- Trial name
- CoQualSEP (NCT01392872)
- Testing
- Neuropsychological assessment
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Sclerosis, Relapsing-Remitting
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlled study in subjects with Relapsing Forms of Multiple Sclerosis (RMS) to assess the efficacy, safety and tolerability of GA Depot…
- Trial name
- NCT04121221
- Testing
- GA Depot
- Where
- 112 sites in United States, Belarus and 8 more
- Volunteers
- 1,016 people
- Sponsor
- Mapi Pharma Ltd.
Multiple Sclerosis (MS) - Relapsing-remitting, Mediterranean Diet
Effect of Low Histamine-Based Modified Mediterranean Diet in Multiple Sclerosis
This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- HistaMed-MS (NCT07501520)
- Testing
- Low Histamine-Based Modified Mediterranean Diet, Traditional Mediterranean Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people
- Sponsor
- Firat University